News US drug strategy

The new US drug strategy, the first to be published under the Obama administration, was released yesterday. The strategy’s appearance was heralded by the Whitehouse with claims of a new direction for US drug policy, and a new emphasis on combating the problems around illicit drug use by focusing on the demand side of the equation. This tactic is based around a broad set of community based prevention interventions, and an expansion of drug treatment into mainstream healthcare. And while the language itself continues to be rejected, the strategy involves measures which embody the principles of harm reduction.

The strategy can thus be said to build on the administration’s movement away from drug war rhetoric, its repeal of the ban on federal funding for needle exchange, and its acceptance of (or non-interference in) state-level medical cannabis provision. There are also encouraging signs that congress will, over the next year, end the mandatory minimum sentencing disparities between powder cocaine and crack, laws which are racist in effect if not intention.

At the same time, beneath the rhetoric of change there are large areas of continuity with the drug war, readily apparent in the fact that two thirds of the budget remains devoted to law enforcement. A more profound and significant break with the failures of the past would be demonstrated by a strategy aimed not so much at stopping or reducing drug use as such, but at minimising the harms associated with both drugs and drug policies. These harms are tightly interwoven with the mass incarceration of US citizens for non-violent drug offences. Nonetheless, such changes as there are should be welcomed, and it will be interesting to compare the performance of Britain’s new government when its new drug strategy appears.